NASDAQ:OMGA • US68217N1054
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for OMEGA THERAPEUTICS INC (OMGA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-11-15 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-07 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-06-18 | Raymond James | Initiate | Outperform |
| 2024-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-04-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-03 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-04-01 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-01-04 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-11-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-10 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-09-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-04 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-06-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-08 | Chardan Capital | Reiterate | Buy |
| 2023-03-31 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-24 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-10 | JonesTrading | Initiate | Buy |
| 2023-03-03 | Piper Sandler | Maintains | Overweight |
| 2022-12-08 | HC Wainwright & Co. | Initiate | Buy |
| 2022-09-23 | Chardan Capital | Initiate | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Neutral |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.07M | 3.094M 49.47% | 8.706M 181.38% | 4.394M -49.53% | 6.747M 53.55% | 34.053M 404.71% | 259.91M 663.25% | 527.63M 103.00% | 885.1M 67.75% | 27.617M -96.88% | 16.001M -42.06% | ||
| EBITDA YoY % growth | -64.79M -135.60% | -101.21M -56.21% | -98.693M 2.49% | -61.49M 37.70% | -60.792M 1.13% | -87.822M -44.46% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -66.18M -130.99% | -102.77M -55.29% | -100.261M 2.44% | -66.505M 33.67% | -45.513M 31.56% | -26.244M 42.34% | -66.52M -153.47% | 113.08M 269.99% | 300.14M 165.42% | 554.15M 84.63% | 9.402M -98.30% | -2.675M -128.46% | |
| Operating Margin | N/A | -4,964.73% | -3,240.50% | -763.89% | -1,035.81% | -388.97% | -195.34% | 43.51% | 56.88% | 62.61% | 34.04% | -16.72% | |
| EPS YoY % growth | N/A | -2.14 18.13% | -1.81 15.42% | -1.19 34.35% | -0.80 32.62% | -0.45 43.95% | -0.77 -70.45% | 1.60 309.33% | 3.88 142.04% | 6.10 57.37% | 0.97 -84.11% | N/A |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.21 43.49% | -0.18 50.42% | -0.20 33.70% | -0.20 32.00% | -0.22 -7.32% |
| Revenue Q2Q % growth | 1.456M 47.22% | 1.099M -53.43% | 1.099M -48.50% | 1.099M -57.92% | 1.099M -24.52% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.984M 42.10% | -10.093M 50.65% | -11.035M 33.44% | -11.719M 28.63% | -12.666M -5.69% |
All data in USD
7 analysts have analysed OMGA and the average price target is 13.26 USD. This implies a price increase of 9198.74% is expected in the next year compared to the current price of 0.1426.
The consensus EPS estimate for the next earnings of OMEGA THERAPEUTICS INC (OMGA) is -0.21 USD and the consensus revenue estimate is 1.46M USD.
The number of analysts covering OMEGA THERAPEUTICS INC (OMGA) is 7.